Navigation Links
National Cancer Institute: Battling Cancer and a Recession
Date:1/16/2009

DURHAM, N.C., Jan. 16 /PRNewswire-USNewswire/ -- Despite difficult financial times and flat federal funding of biomedical research, five important actions -- which can be implemented rapidly and at modest cost -- can yield dramatic results for patients and the public. So write three leaders of the National Cancer Institute (NCI) in a commentary published today by "The Oncologist."

(Logo: http://www.newscom.com/cgi-bin/prnh/20080627/CLF051LOGO )

In the article, James H. Doroshow, M.D., director of NCI's Division of Cancer Treatment and Diagnosis; Robert T. Croyle, Ph.D., director of its Division of Cancer Control and Population Sciences; and John E. Niederhuber, M.D., director of the National Cancer Institute recommend:

-- Significantly increasing enrollment of Medicare patients into cancer clinical trials, by modestly increasing the Medicare reimbursement rate for the type of office visits required for patients entered into clinical trials.

-- Increasing collaborations between NCI and the Centers for Medicare and Medicaid Services to determine the effectiveness of new cancer drugs.

-- Undertaking a national outcomes research demonstration project, to help close the gap between the rapid pace of innovation in biomedicine and our ability to harness it to improve population health.

-- Leveraging existing tobacco-control collaborations and possible new authorities at the U.S. Food and Drug Administration, tackle tobacco control with the seriousness and energy it deserves.

-- Disseminating information about and implementing greater levels of colorectal cancer screening.

This short list of actions, the authors propose, "has the potential for substantial clinical and public health impact at minimal cost. All of these can be implemented quickly because they build directly on existing research, clinical, and public health models." Taken together, the total cost of these five initiatives would be $210 million.

Bruce A. Chabner, M.D., editor-in-chief of "The Oncologist" in a lead editorial summarized that, "as a nation, we must proceed with the conquest of this disease, despite our economic limitations. The scientific opportunities have never been greater and, as our population ages and other diseases come under control, cancer will play an increasingly dominant place in America's health ... and health policy." "On the eve of the inauguration of President-elect Obama," Dr. Chabner continued, "there is enormous opportunity, and medical research is perhaps the area in which our country has its greatest leadership role and its greatest potential for economic return on its investment."

Both papers published by "The Oncologist," are freely available: Chabner Editorial: http://theoncologist.com/cgi/reprint/theoncologist.2009-0001v1

    NCI Commentary:
http://theoncologist.com/cgi/reprint/theoncologist.2008-0270v1


About AlphaMed Press

AlphaMed Press publishes the internationally renowned journals, "Stem Cells" and "The Oncologist." "Stem Cells," now in its 27th year, is the oldest and one of the world's top-tier peer-reviewed monthly journals in the fast-paced area of stem cells and regenerative medicine. "The Oncologist," in its 14th year, is a premier peer-reviewed monthly journal dedicated to physicians entrusted with the care of cancer patients. View AlphaMed Press journals at http://www.alphamedpress.org.

Contact:

Dr. Martin J. Murphy, Executive Editor: 919.641.5304; Martin.Murphy@TheOncologist.com

Dr. Bruce A. Chabner, Editor-in-Chief: 617-724-3136; bchabner@partners.org


'/>"/>
SOURCE AlphaMed Press
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
6. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
7. Arrow International Files and Mails Definitive Proxy Materials
8. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
9. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
10. Viragen International to Reverse Split Its Common Stock
11. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
(Date:6/23/2016)... Prairie, WI (PRWEB) , ... June 23, 2016 ... ... consultancy focused on quality, regulatory and technical consulting, provides a free webinar ... is presented on July 13, 2016 at 12pm CT at no charge. , ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):